Coloplast A/S - Updated Financial Calendar 2025-26

Please see enclosed pdf. Update to Financial Calendar Dates Coloplast has updated the dates in its financial calendar for the publication of the FY Financial Statements 2025/26 and the Annual General ...

Coloplast A/S - Interim Financial Report, Q1 2025/26

Interim financial results, Q1 2025/261 October 2025 - 31 December 2025 Coloplast delivered Q1 organic growth of 6% and EBIT ...
Seeking Alpha

Coloplast: Cheaper Than In The Past, But Not Yet A Bargain

Coloplast's stock price has declined by 25% since April 2023, making it more attractive but still overvalued based on fundamentals and valuation multiples. Recent quarterly results show revenue growth ...
Investing.com South Africa

Coloplast shares drop 7% as Kerecis reimbursement hit weakens Q1 results

Investing.com -- Coloplast shares tumbled on Friday after the medical equipment maker posted a softer-than-expected start to its 2025/26 year, with underlying growth and profitability weighed down by ...
FierceBiotech

Coloplast casts $1.3B to reel in fish-skin-based wound care company Kerecis

There’s something fishy about Coloplast’s latest megadeal—literally. The Danish medtech announced (PDF) plans on Friday to acquire Kerecis, which uses fish skin as the basis of its wound care products ...
Seeking Alpha

Coloplast: Finally Getting Buyable

Coloplast is a global leader in specialized intimate healthcare, with strong innovation, high margins, and a defensible moat in core segments. Despite a 20% share price drop, I see upside potential, ...
MM&M

Coloplast buys up fish skin wound care biotech Kerecis for $1.3B

Coloplast announced it will acquire wound care product company Kerecis for $1.3 billion. The acquisition will give Coloplast an opportunity to “strategically strengthen [its] presence in the advanced ...
manilatimes

Coloplast A/S CEO Kristian Villumsen steps down as of today

Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO. As the company is entering into a new strategy ...
Nasdaq

Coloplast launches male catheter designed to reduce the risk of urinary tract infections

The new intermittent catheter Luja™ addresses important risk factors for urinary tract infections, a significant burden for people using intermittent catheters as well as healthcare systems as a whole ...
Reuters

Coloplast buys fish skin woundcare firm for up to $1.3 billion

COPENHAGEN, July 7 (Reuters) - Coloplast (COLOb.CO), opens new tab has agreed to buy Iceland-based Kerecis, a biologic wound care firm that uses fish skin to develop tissue-transplant products, for up ...
Morningstar

Coloplast's Strength in Innovation Fortifies Its Narrow Moat

Coloplast historically has introduced consistent innovation in its ostomy-care products, including different types of adhesives, one- and two-piece devices, and irrigation systems. Finally, we note ...
Morningstar

Coloplast's Impressive Track Record for Innovation Adds Up to a Narrow Moat

Coloplast's wound-care portfolio is relatively limited, especially when compared with the breadth of products from Smith & Nephew, and ConvaTec, which includes high-tech solutions such as ...